Drug intelligence / Profile preview

Orogen B-cell disorders program

Development stage: Preclinical
Lead developer: OroGen BioSciences
Modality: Small Molecules

Overview

Orogen Therapeutics is developing a small molecule program targeting undisclosed biological pathways for the treatment of B-cell disorders. This program is part of Orogen's "Small-Molecule Alternatives to Biologics" (SMABs) platform, which aims to create orally available small molecules that mimic the efficacy and specificity of biologic therapies. The program is currently in the hit identification stage and is characterized by novel composition of matter and potentially novel mechanisms of action. It represents an early-stage effort to expand the company's pipeline into immunology and B-cell mediated pathologies.

Other names: Undisclosed targets program (B-cell disorders)

Beyond the preview

Go deeper on Orogen B-cell disorders program.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Orogen B-cell disorders program.

Explore the full profile